Antiangiogenic Agents in First-Line and Second-Line Therapy for Advanced Colorectal Cancer

Por Bendell, Johanna
Publicado em 2007

Donating Tissue for Research: Patient and Provider Perspectives

Por Baer, Allison R., Smith, Mary Lou, Bendell, Johanna C.
Publicado em 2011

Cancer Genomics: Conducting Exemplary Trials With Biospecimen and Biomarker Components

Por Baer, Allison R., Collyar, Deborah, Smith, Mary Lou, Bendell, Johanna
Publicado em 2010

Evolving Diagnostic and Treatment Strategies for Pancreatic Neuroendocrine Tumors

Por Kulke, Matthew H, Bendell, Johanna, Kvols, Larry, Picus, Joel, Pommier, Rodney, Yao, James
Publicado em 2011

A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second‐Line Treatment of Metastatic KRAS Mutant Colorectal Adenocar...

Por Hecht, J. Randolph, Benson, Al B., Vyushkov, Dmitry, Yang, Yingsi, Bendell, Johanna, Verma, Udit
Publicado no Oncologist (2017)

A Phase II Randomized, Double‐Blind, Placebo‐Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First‐Line Treatment of Pancreatic Adenocarcinoma...

Por Benson, Al B., Wainberg, Zev A., Hecht, J. Randolph, Vyushkov, Dmitry, Dong, Hua, Bendell, Johanna, Kudrik, Fred
Publicado no Oncologist (2017)

Targeted Therapy in Rectal Cancer

Por WILLETT, CHRISTOPHER G., DUDA, DAN G., CZITO, BRIAN G., BENDELL, JOHANNA C., CLARK, JEFFREY W., JAIN, RAKESH K.
Publicado em 2007

A Phase II Study of Oxaliplatin, Dose-Intense Capecitabine and High-Dose Bevacizumab in the Treatment of Metastatic Colorectal Cancer

Por Wong, Nan Soon, Fernando, Nishan H., Bendell, Johanna C., Morse, Michael A., Blobe, Gerard C., Honeycutt, Wanda, Pang, Herbert, Hurwitz, Herbert I.
Publicado em 2011

Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors

Por Bendell, Johanna C., Patel, Manish R., Yoshida, Kenichiro, Seraj, Jabed, Weaver, Racquel, Lemech, Charlotte, Todaro, Thomas G., Pant, Shubham, Arkenau, Hendrik-Tobias
Publicado no Cancer Chemother Pharmacol (2016)

Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer

Por Bendell, Johanna C., Rosen, Lee S., Mayer, Robert J., Goldman, Jonathan W., Infante, Jeffrey R., Benedetti, Fabio, Lin, Donghu, Mizuguchi, Hirokazu, Zergebel, Christopher, Patel, Manish R.
Publicado no Cancer Chemother Pharmacol (2015)

Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer

Por Bendell, Johanna C., Rosen, Lee S., Mayer, Robert J., Goldman, Jonathan W., Infante, Jeffrey R., Benedetti, Fabio, Lin, Donghu, Mizuguchi, Hirokazu, Zergebel, Christopher, Patel, Manish R.
Publicado no Cancer Chemother Pharmacol (2015)

A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors

Por Pant, Shubham, Burris, Howard A., Moore, Kathleen, Bendell, Johanna C., Kurkjian, Carla, Jones, Suzanne F., Moreno, Ofir, Kuhn, John G., McMeekin, Scott, Infante, Jeffrey R.
Publicado em 2013

A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Por Bendell, Johanna C., Zakari, Ahmed, Peyton, James D., Boccia, Ralph, Moskowitz, Mark, Gian, Victor, Lipman, Andrew, Waterhouse, David, LoCicero, Richard, Earwood, Chris, Lane, Cassie M., Meluch, Anthony
Publicado no Oncologist (2016)

Treatment Patterns and Clinical Outcomes in Patients With Metastatic Colorectal Cancer Initially Treated with FOLFOX–Bevacizumab or FOLFIRI–Bevacizumab: Results From ARIES, a Bevac...

Por Bendell, Johanna C., Bekaii-Saab, Tanios S., Cohn, Allen L., Hurwitz, Herbert I., Kozloff, Mark, Tezcan, Haluk, Roach, Nancy, Mun, Yong, Fish, Susan, Flick, E. Dawn, Dalal, Darshan, Grothey, Axel
Publicado em 2012

Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: A Sarah Cannon Research Institute phase II trial

Por Infante, Jeffrey R., Arkenau, Hendrik-Tobias, Bendell, Johanna C., Rubin, Mark S., Waterhouse, David, Jones, George Tripp, Spigel, David R., Lane, Cassie M., Hainsworth, John D., Burris III, Howard A.
Publicado em 2013

A Phase II study of Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in the Treatment of Metastatic Colorectal Cancer

Por WONG, NAN SOON, FERNANDO, NISHAN H., NIXON, ANDREW B., CUSHMAN, STEPHANIE, AKLILU, MEBEA, BENDELL, JOHANNA C., MORSE, MICHAEL A., BLOBE, GERARD C., ASHTON, JILL, PANG, HERBERT, HURWITZ, HERBERT I.
Publicado em 2011

Phase 1, Open-Label, Dose Escalation, Safety, and Pharmacokinetics Study of ME-344 as a Single Agent in Patients With Refractory Solid Tumors

Por Bendell, Johanna C, Patel, Manish R, Infante, Jeffrey R, Kurkjian, Carla D, Jones, Suzanne F, Pant, Shubham, Burris, Howard A, Moreno, Ofir, Esquibel, Vanessa, Levin, Wendy, Moore, Kathleen N
Publicado no Cancer (2015)

A Phase II Trial of Bevacizumab plus Everolimus for Patients with Refractory Metastatic Colorectal Cancer

Por Altomare, Ivy, Bendell, Johanna C., Bullock, Karen E., Uronis, Hope E., Morse, Michael A., Hsu, S. David, Zafar, S. Yousuf, Blobe, Gerard C., Pang, Herbert, Honeycutt, Wanda, Sutton, Linda, Hurwitz, Herbert I.
Publicado em 2011

CONCURRENT CHEMORADIOTHERAPY IN RESECTED EXTRAHEPATIC CHOLANGIOCARCINOMA

Por Nelson, John W., Ghafoori, A. Paiman, Willett, Christopher G., Tyler, Douglas S., Pappas, Theodore N., Clary, Bryan M., Hurwitz, Herbert I., Bendell, Johanna C., Morse, Michael A., Clough, Robert W., Czito, Brian G.
Publicado em 2008

A phase I study of ABT-510 plus bevacizumab in advanced solid tumors

Por Uronis, Hope E, Cushman, Stephanie M, Bendell, Johanna C, Blobe, Gerard C, Morse, Michael A, Nixon, Andrew B, Dellinger, Andrew, Starr, Mark D, Li, Haiyan, Meadows, Kellen, Gockerman, Jon, Pang, Herbert, Hurwitz, Herbert I
Publicado em 2013